Cancer Screening Utilization Rates and Cancer Screening Perspectives of Hospitalized Women

NCT ID: NCT04162925

Last Updated: 2022-12-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

700 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-31

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Breast and colon cancers are commonly diagnosed cancers among women after skin cancer in Maryland. Patients' preferences for cancer screening are known to significantly influence utilization, and thus impact health outcomes. In a recent study the investigators conducted at Johns Hopkins Bayview Medical Center, the investigators observed that among women age 50-75 years admitted to general medicine services over 4-month period, 40% were non-adherent to breast cancer screening (overdue) despite being insured.

Therefore, the investigators propose to establish a cohort of hospitalized women to help the investigators develop successful interventions for enhancing breast cancer screening utilization in this group. In following a cohort prospectively, the investigators intend to both reaffirm the results from the investigators' previous study and determine whether the patterns of mammographic screening improve over time as a result of the investigators' interventions. Among non-adherent (overdue) women, the investigators will educate and encourage these women to undergo outpatient screening mammography.

To more comprehensively assess the preventive health in this cohort, the investigators will assess the cohort's adherence to colon cancer screening recommendation and barriers to colon cancer screening.

In addition the investigators will also like to encourage the hospitalists and house staff taking care of these patients to perform oral cancer screen among women who smoke (non-adherent to breast cancer screening) Finally the investigators will also like to ask the perspective of cancer screening among these women.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Screening

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Cancer screening utilization rates and cancer screening perspective of hospitalized women on internal medicine service
Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cancer screening cohort

All women in this study to be evaluated for cancer screening utilization rates (breast, colon and oral cancers) and cancer screening perspectives of these hospitalized women.

The intervention will be a cancer screening education.

Group Type EXPERIMENTAL

Cancer screening education for breast, colon and oral cancers

Intervention Type BEHAVIORAL

Bedside education one-on-one by showing screening video and handouts at the end of educational session for breast, colon and oral cancer. Patient who are agreeable to oral cancer screen during hospitalization perform oral cancer screening

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cancer screening education for breast, colon and oral cancers

Bedside education one-on-one by showing screening video and handouts at the end of educational session for breast, colon and oral cancer. Patient who are agreeable to oral cancer screen during hospitalization perform oral cancer screening

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women between the ages of 50 to 75 years admitted to medicine service at Johns Hopkins Bayview Medical Center
* cancer free at baseline (excluding skin cancers)
* willing to participate voluntarily

Exclusion Criteria

* history of breast cancer or mastectomy
* history of other cancers (except skin) or serious comorbidities making life expectancy \<10 years
* pregnancy
* dementia
* chronic disability (unable to stand or nursing home resident)
* current admission because of acute coronary event (heart attack) or stroke or pulmonary embolism
* chronic kidney disease on hemodialysis
* history of BRCA1 or BRCA2 gene mutation
* current admission for cellulitis or abscess of breast
Minimum Eligible Age

50 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

State of Maryland

OTHER_GOV

Sponsor Role collaborator

Johns Hopkins University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Waseem Khaliq, MD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University

References

Explore related publications, articles, or registry entries linked to this study.

Olayinka O, Gnanaraj J, Khaliq W. Hospitalized Women's Willingness to Pay for Inpatient Screening Colonoscopy. Womens Health Rep (New Rochelle). 2022 Sep 13;3(1):768-773. doi: 10.1089/whr.2022.0014. eCollection 2022.

Reference Type DERIVED
PMID: 36185070 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IO90059879

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

IRB00049608

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.